ArticlePathogens (Basel, Switzerland)2023
Potential Therapeutic Target and Vaccines for SARS-CoV-2.
Mohamed A Hussain, Mohamed M Hassan, Bashir Abdrhman Bashir, Tarig A Gamar, Elmuaiz Gasmalbari, Ahmed Osman Mohamed, Wadah Osman, Asmaa E Sherif, Abdelaziz Elgaml, Aisha A Alhaddad and 7 more
Open access · goldAbstract read
In one paragraphArticle in Pathogens (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 88% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed, 0 citations in OpenAlex.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
17 authors at 10 institutions in 3 countries.
Mohamed A HussainDepartment of Pharmaceutical Microbiology, Faculty of Pharmacy, International University of Africa, Khartoum 11111, Sudan.ORCID 0000-0003-1487-2005 Mohamed M HassanDepartment of Hematology, Faculty of Medical Laboratory Science, National University, Khartoum 11111, Sudan.ORCID 0000-0003-1544-7932 Bashir Abdrhman BashirDepartment of Hematology, Faculty of Medical Laboratory Sciences, Port Sudan Ahlia College, Port Sudan 33312, Sudan.ORCID 0000-0002-5089-9531 Tarig A GamarDepartment of Medical Parasitology, Faculty of Medical Laboratory Sciences, University of Sciences and Technology, Khartoum North 13311, Sudan.ORCID 0000-0002-4655-9446 Elmuaiz GasmalbariFaculty of Medicine, Omdurman Islamic University, Al Khartoum 14415, Sudan.
Ahmed Osman MohamedDepartment of Pharmaceutical Microbiology, Faculty of Pharmacy, International University of Africa, Khartoum 11111, Sudan.ORCID 0000-0001-5472-1151 Wadah OsmanDepartment of Pharmacognosy, Faculty of Pharmacy, Prince Sattam Bin Abdulaziz University, Al-Kharj 11942, Saudi Arabia.
Asmaa E SherifDepartment of Pharmacognosy, Faculty of Pharmacy, Prince Sattam Bin Abdulaziz University, Al-Kharj 11942, Saudi Arabia.
Abdelaziz ElgamlMicrobiology and Immunology Department, Faculty of Pharmacy, Mansoura University, Mansoura 35511, Egypt.ORCID 0000-0001-6790-5849 Aisha A AlhaddadDepartment of Pharmacology and Toxicology, College of Pharmacy, Taibah University, Al-Madinah Al-Munawwarah 30078, Saudi Arabia.
Kholoud F GhazawiClinical Pharmacy Department, College of Pharmacy, Umm Al-Qura University, Makkah 24382, Saudi Arabia.
Samar F MiskiDepartment of Pharmacology and Toxicology, College of Pharmacy, Taibah University, Al-Madinah Al-Munawwarah 30078, Saudi Arabia.
Bayan E AinousahDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, Umm Al-Qura University, Makkah 21955, Saudi Arabia.ORCID 0009-0009-6221-4067 Yusra Saleh AndijaniDepartment of Pharmacology and Toxicology, College of Pharmacy, Taibah University, Al-Madinah Al-Munawwarah 30078, Saudi Arabia.ORCID 0000-0001-6535-5142 Sabrin R M IbrahimPreparatory Year Program, Department of Chemistry, Batterjee Medical College, Jeddah 21442, Saudi Arabia.ORCID 0000-0002-6858-7560 Gamal A MohamedDepartment of Natural Products and Alternative Medicine, Faculty of Pharmacy, King Abdulaziz University, Jeddah 21589, Saudi Arabia.ORCID 0000-0002-2971-6008 Ahmed AshourDepartment of Pharmacognosy, Faculty of Pharmacy, Prince Sattam Bin Abdulaziz University, Al-Kharj 11942, Saudi Arabia.ORCID 0000-0003-4081-0369 Prince Sattam Bin Abdulaziz University · SATaibah University · SAInternational University of Africa · SDUmm al-Qura University · SABatterjee Medical CollegeDamietta University · EGKing Abdulaziz University · SANational University · SDOmdurman Islamic University · SDUniversity of Medical Sciences and Technology · SD
Funding
This study is supported via funding from Prince Sattam bin Abdulaziz University. Project number (PSAU/2023/R/1444) PSAU/2023/R/1444
6 · The paper itselfAbstract
The coronavirus has become the most interesting virus for scientists because of the recently emerging deadly SARS-CoV-2. This study aimed to understand the behavior of SARS-CoV-2 through the comparative genomic analysis with the closest one among the seven species of coronavirus that infect humans. The genomes of coronavirus species that infect humans were retrieved from NCBI, and then subjected to comparative genomic analysis using different bioinformatics tools. The study revealed that SARS-CoV-2 is the most similar to SARS-CoV among the coronavirus species. The core genes were shared by the two genomes, but there were some genes, found in one of them but not in both, such as ORF8, which is found in SARS-CoV-2. The ORF8 protein of SARS-CoV-2 could be considered as a good therapeutic target for stopping viral transmission, as it was predicted to be a transmembrane protein, which is responsible for interspecies transmission. This is supported by the molecular interaction of ORF8 with both the ORF7 protein, which contains a transmembrane domain that is essential to retaining the protein in the Golgi compartment, and the S protein, which facilitates the entry of the coronavirus into host cells. ORF1ab, ORF1a, ORF8, and S proteins of SARS-CoV-2 could be immunogenic and capable of evoking an immune response, which means that these four proteins could be considered a potential vaccine source. Overall, SARS-CoV-2 is most related to SARS-CoV. ORF8 could be considered a potential therapeutic target for stopping viral transmission, and ORF1ab, ORF1a, ORF8, and the S proteins of SARS-CoV-2 could be utilized as a potential vaccine source.
Indexed as
comparative genomicscoronavirusCOVID-19genes and proteins analysishealth and well-beingSDGstherapeutic target and vaccine
Identifiers
PMID37513773
PMCPMC10386482
OpenAlexW4383955223
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390